

Leukine® Prior Authorization Request Form (Page 1 of 2)

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information <small>(required)</small>					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information <small>(required)</small>					
Select the diagnosis below: <input type="checkbox"/> Acute myeloid leukemia (AML) following induction or consolidation chemotherapy <input type="checkbox"/> Bone marrow transplant (BMT)/stem cell transplant <input type="checkbox"/> HIV-related neutropenia <input type="checkbox"/> Neutropenia associated with cancer chemotherapy – dose dense chemotherapy <input type="checkbox"/> Primary prophylaxis of chemotherapy-induced febrile neutropenia (FN) <input type="checkbox"/> Treatment of febrile neutropenia (FN) <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
For all diagnoses, answer the following: Does the patient have history of failure, contraindication, or intolerance to Zarxio? <input type="checkbox"/> Yes <input type="checkbox"/> No Is Leukine prescribed by a hematologist/oncologist? <input type="checkbox"/> Yes <input type="checkbox"/> No If “no” to the above question, is Leukine prescribed in consultation with a hematologist/oncologist? <input type="checkbox"/> Yes <input type="checkbox"/> No Document the following: Chemotherapy regimen and frequency: _____ Number of chemotherapy cycles the patient has received: _____ Total number of cycles expected: _____					
For bone marrow transplant (BMT)/stem cell transplant, also answer the following: Select the procedure for which Leukine is being used: <input type="checkbox"/> For patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by autologous or allogeneic BMT <input type="checkbox"/> For mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis <input type="checkbox"/> For peripheral stem cell transplant (PSCT) patients who have received myeloablative chemotherapy					
For HIV-related neutropenia, also answer the following: Is the absolute neutrophil count (ANC) $\leq 1,000$ cells/mm ³ ? <input type="checkbox"/> Yes <input type="checkbox"/> No Is Leukine prescribed by a hematologist/oncologist or an infectious disease specialist? <input type="checkbox"/> Yes <input type="checkbox"/> No If “no” to the above question, is Leukine prescribed in consultation with a hematologist/oncologist or an infectious disease specialist? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For neutropenia associated with cancer dose dense chemotherapy, also answer the following: Is the patient receiving National Cancer Institute’s Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer (doxorubicin, cyclophosphamide, and paclitaxel)? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient receiving a dose-dense chemotherapy regimen for which the incidence of febrile neutropenia is unknown? <input type="checkbox"/> Yes <input type="checkbox"/> No					

Leukine® Prior Authorization Request Form (Page 2 of 2)

For primary prophylaxis of chemotherapy-induced febrile neutropenia (FN), also answer the following:

- Is the patient receiving a chemotherapy regimen associated with >20% incidence of FN? Yes No
 Is the patient receiving a chemotherapy regimen associated with 10-20% incidence of FN? Yes No
 Does the patient have one or more risk factors associated with chemotherapy-induced infection, FN or neutropenia? Yes No

For treatment of febrile neutropenia (FN), also answer the following:

- Is the patient receiving myelosuppressive anticancer drugs associated with neutropenia (ANC ≤ 500 cells/mm³)? Yes No
 Does the patient have FN at high risk for infection-associated complications? Yes No
 Is there a history of FN during a previous course of chemotherapy? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above.
Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.

I certify, to the best of my knowledge, the statements and information provided on this form are factual and correct.

Provider/Representative (and Title): _____ Date: _____

PROACT INTERNAL USE ONLY:					
Clinical Review Decision					
	Approved, through				
	Denied (documentation attached, if necessary)				
Tracking:					
1 st Attempt		2 nd Attempt		Letter Mailed:	